

EXHIBIT 6

To

Memorandum In Support of TriPath Imaging, Inc.'s Motion to Exclude
Defenses Based on Cytc's CDS-1000

Civil Action No. 03-11142 [DPW] - Lead Case

Filed May 5, 2005

**WILMER CUTLER PICKERING
HALE AND DORR LLP**

Patrick M. Callahan

60 STATE STREET
BOSTON, MA 02109
+1 617 526 6667
+1 617 526 5000 fax
patrick.callahan@wilmerhale.com

March 16, 2005

By Facsimile

Charles A. Burke, Esq.
Womble Carlyle Sandridge & Rice PLLC
One West Fourth Street
Winston-Salem, NC 27101

Re: Cytec Corporation v. TriPath Imaging, Inc. No. 03-11142 (DPW) (D. Mass.)

Dear Charles:

In the March 7th expert report of Dr. John C. Russ, TriPath asserts -- for the first time -- that the ThinPrep Imaging System infringes claim 19 of the '377 Patent. TriPath had *never* previously identified Claim 19 in its answers or supplemental answers to Cytec's interrogatories, which specifically called for such information. See TriPath's December 15, 2003 Answer and Objections to Interrogatory No. 4 (identifying claims 1 and 16 of the '377 Patent); TriPath's September 27, 2004 Supplemental Answer and Objections to Interrogatory No. 4 (identifying claims 1-4, 6-11, 13-16, 18, 20, 22-26 of the '377 Patent).

The rules preclude TriPath from asserting -- after the close of fact discovery -- claims that were not disclosed in its answers to interrogatories. See, e.g., Fed. R. Civ. P. 26(e). Further, there appears to be no justification for TriPath's failure in this regard, since the documents on which Dr. Russ relies for his infringement opinion were among the first produced in this case -- *over a year ago*. See Cytec January 30, 2004 Letter (producing, *inter alia*, C0019683 and C0025278-79). Beyond its failure to comply with the Federal Rules, TriPath's untimely attempt to assert Claim 19 has caused substantial prejudice to Cytec because Cytec was unable to address this claim in its own expert submissions, which were served on the same day we received Dr. Russ's report.

BALTIMORE BERLIN BOSTON BRUSSELS LONDON MUNICH
NEW YORK NORTHERN VIRGINIA OXFORD PRINCETON WALTHAM WASHINGTON

Charles A. Burke, Esq.

March 16, 2005

Page 2

In light of the above, we ask that you immediately withdraw Claim 19 of the '377 Patent. If you refuse to do so, we will move to preclude TriPath from offering evidence of infringement of that claim.

Very truly yours,



Patrick M. Callahan

PMC/jlm

WILMER CUTLER PICKER INC
HALE AND DORR

March 22, 2005

Patrick M. Callahan

60 STATE STREET
BOSTON, MA 02109
+1 617 526 6667
+1 617 526 5000 fax
patrick.callahan@wilmerhale.com

By Facsimile

Charles A. Burke, Esq.
Womble Carlyle Sandridge & Rice PLLC
One West Fourth Street
Winston-Salem, NC 27101


Re: Cytec Corporation v. TriPath Imaging, Inc. No. 03-11142 (DPW) (D. Mass.)

Dear Charles:

I write to follow up on my March 16th letter regarding the expert report of Dr. John Russ.

In that letter, we asked TriPath to withdraw its claim of infringement with respect to Claim 19 of the '377 Patent due to TriPath's failure to assert that claim until after the close of fact discovery and after Cytec had submitted its own expert reports. We have not yet received a response. If we do not hear from you by the end of business tomorrow, we will assume that you do not intend to withdraw that claim, and we will take the issue up with the Court.


Very truly yours,



Patrick M. Callahan

PMC/jlm

BALTIMORE BERLIN BOSTON BRUSSELS LONDON MUNICH
NEW YORK NORTHERN VIRGINIA OXFORD PRINCETON WALTHAM WASHINGTON



One West Fourth Street
Winston-Salem, NC 27101

Telephone: (336) 721-3600
Fax: (336) 721-3660
Web site: www.wcsr.com

Christopher G. Daniel
Direct Dial: (336) 721-3719
Direct Fax: (336) 733-8426
E-mail: cdaniel@wcsr.com

March 23, 2005


Via Facsimile & U.S. Mail

Patrick M. Callahan, Esq.
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, MA 02109

Re: *Cytyc Corporation v. TriPath Imaging, Inc.*
Civil Action No. 03-11142 (DPW)(D. Mass)

Dear Patrick:

We have examined the issue raised in your March 16, 2005 letter regarding Claim 19 of the '377 Patent. This confirms that TriPath's assertion of Claim 19 will be withdrawn.

Sincerely,

Christopher G. Daniel